TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

26 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

09 Dec 2024 17:45:00 By Nasdaq GlobeNewswire

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

05 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

05 Nov 2024 09:15:27 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

04 Oct 2024 09:05:45 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Updates to its Board of Directors

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

24 Apr 2024 16:05:34 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

24 Apr 2024 11:03:30 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

22 Apr 2024 17:01:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Upsized Public Offering

19 Apr 2024 10:05:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

17 Apr 2024 00:30:57 By Nasdaq GlobeNewswire